Search Results - "Schock, Barbara"

Serum Neopterin, an Immune Activation Marker, Independently Predicts Disease Progression in Advanced HIV-1 Infection by Mildvan, Donna, Spritzler, John, Grossberg, Sidney E., Fahey, John L., Johnston, David M., Schock, Barbara R., Kagan, Jonathan

“…Background. CD4+ T lymphocyte (CD4) counts and plasma human immunodeficiency virus (HIV) type 1 RNA concentrations predict clinical outcome in HIV-1 infection…”
Get full text

Can Immune Markers Predict Subsequent Discordance between Immunologic and Virologic Responses to Antiretroviral Therapy? Adult AIDS Clinical Trials Group by Spritzler, John, Mildvan, Donna, Russo, Aleksandra, Asthana, Desh, Livnat, Daniella, Schock, Barbara, Kagan, Jonathan, Landay, Alan, Haas, David W.

“…It is unclear why discordant immunologic and virologic responses occur during therapy for human immunodeficiency virus (HIV) infection. This study examined…”
Get full text

AIDS Clinical Trials Group 5197: A Placebo-Controlled Trial of Immunization of HIV-1-Infected Persons with a Replication-Deficient Adenovirus Type 5 Vaccine Expressing the HIV-1 Core Protein by Schooley, Robert T., Spritzler, John, Wang, Hongying, Lederman, Michael M., Havlir, Diane, Kuritzkes, Daniel R., Pollard, Richard, Battaglia, Cathy, Robertson, Michael, Mehrotra, Devan, Casimiro, Danilo, Cox, Kara, Schock, Barbara

“…Background . Human immunodeficiency virus type 1 (HIV-1)-specific cellular immunity contributes to the control of HIV-1 replication. HIV-1-infected volunteers…”
Get full text

A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy by Gandhi, Rajesh T, O’Neill, David, Bosch, Ronald J, Chan, Ellen S, Bucy, R. Pat, Shopis, Janet, Baglyos, Lynn, Adams, Elizabeth, Fox, Lawrence, Purdue, Lynette, Marshak, Ann, Flynn, Theresa, Masih, Reena, Schock, Barbara, Mildvan, Donna, Schlesinger, Sarah J, Marovich, Mary A, Bhardwaj, Nina, Jacobson, Jeffrey M

“…Abstract Targeting canarypox (CP)-HIV vaccine to dendritic cells (DCs) elicits anti-HIV-1 immune responses in vitro. We conducted a phase I/II clinical trial…”
Get full text

ACTG 5197: A Placebo Controlled Trial of Immunization of HIV-1 Infected Persons with a Replication Deficient Ad5 Vaccine Expressing the HIV-1 Core Protein by Schooley, Robert T., Spritzler, John, Wang, Hongying, Lederman, Michael M., Havlir, Diane, Kuritzkes, Daniel R., Pollard, Richard, Battaglia, Cathy, Robertson, Michael, Mehrotra, Devan, Casimiro, Danilo, Cox, Kara, Schock, Barbara

Get full text

AIDS Clinical Trials Group 5197: A PlaceboControlled Trial of Immunization of HIV1-Infected Persons with a Replication-Deficient Adenovirus Type 5 Vaccine Expressing the HIV-1 Core Protein by SCHOOLEY, Robert T, SPRITZLER, John, CASIMIRO, Danilo, COX, Kara, SCHOCK, Barbara, HONGYING WANG, LEDERMAN, Michael M, HAVLIR, Diane, KURITZKES, Daniel R, POLLARD, Richard, BATTAGLIA, Cathy, ROBERTSON, Michael, MEHROTRA, Devan

Get full text

Immune Reconstitution Is Comparable in Antiretroviral-Naive Subjects after 1 Year of Successful Therapy with a Nucleoside Reverse-Transcriptase Inhibitor– or Protease Inhibitor–Containing Antiretroviral Regimen by Landay, Alan L., Spritzler, John, Kessler, Harold, Mildvan, Donna, Pu, Minya, Fox, Larry, O’Neil, Dorothy, Schock, Barbara, Kuritzkes, Daniel

“…We compared immune restoration in patients who suppressed human immunodeficiency virus type 1 replication after treatment with a protease inhibitor (PI) plus…”
Get full text

Placebo-Controlled Trial of Cyclosporin-A in HIV-1 Disease: Implications for Solid Organ Transplantation by Calabrese, Leonard H, Lederman, Michael M, Spritzler, John, Coombs, Robert W, Fox, Lawrence, Schock, Barbara, Yen-Lieberman, Belinda, Johnson, Ronald, Mildvan, Donna, Parekh, Namita

“…OBJECTIVE:Earlier open-label clinical trials have provided conflicting data on the effects of cyclosporin-A (CsA) on the clinical course and immune status of…”
Get full text

A study of the immunology, virology, and safety of prednisone in HIV-1-infected subjects with CD4 cell counts of 200 to 700 mm(-3) by Wallis, Robert S, Kalayjian, Robert, Jacobson, Jeffrey M, Fox, Lawrence, Purdue, Lynette, Shikuma, Cecilia M, Arakaki, Richard, Snyder, Stuart, Coombs, Robert W, Bosch, Ronald J, Spritzler, John, Chernoff, Miriam, Aga, Evgenia, Myers, Laurie, Schock, Barbara, Lederman, Michael M

“…Adult Clinical Trials Group Study 349 examined the immunology, virology, and safety of 40 mg/d prednisone as an adjunct to antiretroviral therapy in 24…”
Get full text

Serum neopterin, an immune activation marker, independently predicts disease progression in advanced HN-1 infection by MILDVAN, Donna, SPRITZLER, John, GROSSBERG, Sidney E, FAHEY, John L, JOHNSTON, David M, SCHOCK, Barbara R, KAGAN, Jonathan

Get full text

A Phase I, placebo-controlled trial of multi-dose recombinant human interleukin-12 in patients with HIV infection by JACOBSON, Mark A, SPRITZLER, John, LANDAY, Alan, CHAN, Ellen, KATZENSTEIN, David, SCHOCK, Barbara, FOX, Lawrence, ROE, Joanad'Arc, KUNDU, Smriti, POLLARD, Richard

“…Interleukin (IL)-12 is a cytokine that stimulates T lymphocytes and natural killer cells to generate a Type 1 T-helper lymphocyte immune response. The primary…”
Get full text

Daily low-dose subcutaneous interleukin-2 added to single- or dual-nucleoside therapy in HIV infection does not protect against CD4+ T-cell decline or improve other indices of immune function: Results of a randomized controlled Clinical trial (ACTG 248) by VOGLER, Mary A, TEPPLER, Hedy, FRANK, Ian, MILDVAN, Donna, MAHON, Laura F, SCHOCK, Barbara, GELMAN, Rebecca, VALENTINE, Fred, LEDERMAN, Michael M, POMERANTZ, Roger J, POLLARD, Richard B, WENG CHERNG, Deborah, GONZALEZ, Charles J, SQUIRES, Kathleen E

“…Approaches to preserve or enhance immune function in HIV-1 infection are needed. To examine the ability of daily low-dose interleukin-2 (IL-2) in combination…”
Get full text

A reporting tool for real-time assessment of study data availability by Bosch, Ronald J, Pierce, Casey, Spritzler, John, Kendall, Michelle A, Jacobson, Jeffrey M, Schock, Barbara, Siminski, Suzanne

“…A simple framework for assessing and reporting data availability in an ongoing clinical trial is described. Protocol requirements, visit schedules and data…”
Get more information

A Study of the immunology, virology, and safety of prednisone in HIV- 1-infected subjects with CD4 cell counts of 200 to 700 mm-3 by WALLIS, Robert S, KALAYJIAN, Robert, SPRITZLER, John, CHERNOFF, Miriam, AGA, Evgenia, MYERS, Laurie, SCHOCK, Barbara, LEDERMAN, Michael M, JACOBSON, Jeffrey M, FOX, Lawrence, PURDUE, Lynette, SHIKUMA, Cecilia M, ARAKAKI, Richard, SNYDER, Stuart, COOMBS, Robert W, BOSCH, Ronald J

“…Adult Clinical Trials Group Study 349 examined the immunology, virology, and safety of 40 mg/d prednisone as an adjunct to antiretroviral therapy in 24…”
Get full text

Brief Report: A Study of the Immunology, Virology, and Safety of Prednisone in HIV-1-Infected Subjects with CD4 Cell Counts of 200 to 700 mm-3 by Wallis, Robert S, Kalayjian, Robert, Jacobson, Jeffrey M, Fox, Lawrence, Purdue, Lynette, Shikuma, Cecilia M, Arakaki, Richard, Snyder, Stuart, Coombs, Robert W, Bosch, Ronald J, Spritzler, John, Chernoff, Miriam, Aga, Evgenia, Myers, Laurie, Schock, Barbara, Lederman, Michael M

“…Adult Clinical Trials Group Study 349 examined the immunology, virology, and safety of 40 mg/d prednisone as an adjunct to antiretroviral therapy in 24…”
Get full text

Identifying Extension Opinion Leaders by Schock, Barbara F, Matthews, Lillian B

“…The authors report the results of research aimed at determining who adopts home practices from published information and to what extent these practices are…”
Get more information

Studien zur spatgotischen Baukunst am Oberrhein by Schock-Werner, Barbara, Julier, Jurgen

Get full text

Jürgen Julier: Studien zur spätgotischen Baukunst am Oberrhein (Book Review) by Schock-Werner, Barbara

Get full text

Studien zur spätgotischen Baukunst am Oberrhein by Schock-Werner, Barbara

Get full text